4D Molecular Therapeutics (FDMT) FCF Margin (2020 - 2025)
4D Molecular Therapeutics (FDMT) has disclosed FCF Margin for 6 consecutive years, with 51563.33% as the latest value for Q3 2025.
- On a quarterly basis, FCF Margin rose 94537000.0% to 51563.33% in Q3 2025 year-over-year; TTM through Sep 2025 was 153264.17%, a 53198289.0% increase, with the full-year FY2024 number at 365118.92%, down 36473981.0% from a year prior.
- FCF Margin was 51563.33% for Q3 2025 at 4D Molecular Therapeutics, up from 289620.0% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 142505.26% in Q4 2023 to a low of 4567800.0% in Q4 2024.
- A 5-year average of 362581.88% and a median of 9843.1% in 2023 define the central range for FCF Margin.
- Peak YoY movement for FCF Margin: tumbled -471030526bps in 2024, then skyrocketed 94537000bps in 2025.
- 4D Molecular Therapeutics' FCF Margin stood at 32220.65% in 2021, then surged by 94bps to 1867.55% in 2022, then skyrocketed by 7731bps to 142505.26% in 2023, then plummeted by -3305bps to 4567800.0% in 2024, then skyrocketed by 99bps to 51563.33% in 2025.
- Per Business Quant, the three most recent readings for FDMT's FCF Margin are 51563.33% (Q3 2025), 289620.0% (Q2 2025), and 345635.71% (Q1 2025).